Skip to main content
Top
Published in: Supportive Care in Cancer 1/2009

01-01-2009 | Original Article

Complementary and alternative medicine in patients with chronic lymphocytic leukemia

Authors: Manfred Hensel, Martin Zoz, Anthony D. Ho

Published in: Supportive Care in Cancer | Issue 1/2009

Login to get access

Abstract

Background

Despite the widespread use of complementary and alternative medicine (CAM) in the general population for the treatment of chronic diseases, only few data have been published for patients with leukemia. The aim of this survey was to study systematically the use of CAM in patients with chronic lymphocytic leukemia (CLL).

Patients and methods

A structured questionnaire was sent to 247 CLL patients of all clinical stages and disease durations, treated and untreated. The questionnaire was returned anonymously by 87 patients (35%).

Results

Thirty-nine patients (44%) had used alternative treatments. No correlation was seen with educational level, gender, or previous or current chemotherapy. The most common alternative or complementary treatment modality was vitamin supplementation (26%), followed by mineral (18%), homeopathic (14%), and mistletoe therapy (9.2%). Some 21% of patients considered their alternative treatment as being successful. Most patients reported that they decided to use CAM after conducting a personal investigation and based on the information they found, without outside recommendations (59%). The majority of the patients used patient brochures about CLL as an important source of information (54%), followed by specific lectures (34%) or the internet (32%).

Conclusion

Our data show that patients with CLL use a wide range of CAM, among them potentially harmful methods. Rational, evidence-based medical information about the effects and risks of CAM use should be made available through patient brochures distributed by patient organizations, through information events with lectures, or via the internet.
Literature
1.
go back to reference Angell M, Kassirer JP (1998) Alternative medicine—the risks of untested and unregulated remedies. N Engl J Med 339:839–841PubMedCrossRef Angell M, Kassirer JP (1998) Alternative medicine—the risks of untested and unregulated remedies. N Engl J Med 339:839–841PubMedCrossRef
2.
go back to reference Apel A, Greim B, Konig N, Zettl UK (2006) Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis. J Neurol 253:1331–1336PubMedCrossRef Apel A, Greim B, Konig N, Zettl UK (2006) Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis. J Neurol 253:1331–1336PubMedCrossRef
3.
go back to reference Astin JA (1998) Why patients use alternative medicine: results of a national study. JAMA 279:1548–1553PubMedCrossRef Astin JA (1998) Why patients use alternative medicine: results of a national study. JAMA 279:1548–1553PubMedCrossRef
4.
go back to reference Bagenal FS, Easton DF, Harris E et al (1990) Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet 336:606–610PubMedCrossRef Bagenal FS, Easton DF, Harris E et al (1990) Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet 336:606–610PubMedCrossRef
5.
go back to reference Bowling AC, Stewart TM (2003) Current complementary and alternative therapies for multiple sclerosis. Curr Treat Options Neurol 5:55–68PubMedCrossRef Bowling AC, Stewart TM (2003) Current complementary and alternative therapies for multiple sclerosis. Curr Treat Options Neurol 5:55–68PubMedCrossRef
6.
go back to reference Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739PubMedCrossRef Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739PubMedCrossRef
7.
go back to reference Cassileth BR, Chapman CC (1996) Alternative cancer medicine: a ten-year update. Cancer Invest 14:396–404PubMedCrossRef Cassileth BR, Chapman CC (1996) Alternative cancer medicine: a ten-year update. Cancer Invest 14:396–404PubMedCrossRef
8.
go back to reference Cassileth BR, Vickers AJ (2005) High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care. J Clin Oncol 23:2590–2592PubMedCrossRef Cassileth BR, Vickers AJ (2005) High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care. J Clin Oncol 23:2590–2592PubMedCrossRef
9.
go back to reference Cassileth BR, Lusk EJ, Guerry D et al (1991) Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med 324:1180–1185PubMed Cassileth BR, Lusk EJ, Guerry D et al (1991) Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med 324:1180–1185PubMed
10.
11.
go back to reference Downer SM, Cody MM, McCluskey P et al (1994) Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86–89PubMed Downer SM, Cody MM, McCluskey P et al (1994) Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86–89PubMed
12.
go back to reference Eisenberg DM, Davis RB, Ettner SL et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575PubMedCrossRef Eisenberg DM, Davis RB, Ettner SL et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575PubMedCrossRef
13.
go back to reference Eisenberg DM, Kessler RC, Foster C et al (1993) Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328:246–252PubMedCrossRef Eisenberg DM, Kessler RC, Foster C et al (1993) Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328:246–252PubMedCrossRef
14.
15.
go back to reference Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 83:777–782PubMedCrossRef Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 83:777–782PubMedCrossRef
16.
go back to reference Fisher P, Ward A (1994) Complementary medicine in Europe. BMJ 309:107–111PubMed Fisher P, Ward A (1994) Complementary medicine in Europe. BMJ 309:107–111PubMed
17.
go back to reference Gertz MA, Bauer BA (2001) Caring (really) for patients who use alternative therapies for cancer. J Clin Oncol 19:4346–4349PubMed Gertz MA, Bauer BA (2001) Caring (really) for patients who use alternative therapies for cancer. J Clin Oncol 19:4346–4349PubMed
18.
go back to reference Grothey A, Duppe J, Hasenburg A, Voigtmann R (1998) [Use of alternative medicine in oncology patients]. Dtsch Med Wochenschr 123:923–929PubMedCrossRef Grothey A, Duppe J, Hasenburg A, Voigtmann R (1998) [Use of alternative medicine in oncology patients]. Dtsch Med Wochenschr 123:923–929PubMedCrossRef
19.
go back to reference Gupta M, Shafiq N, Kumari S, Pandhi P (2002) Patterns and perceptions of complementary and alternative medicine (CAM) among leukaemia patients visiting haematology clinic of a north Indian tertiary care hospital. Pharmacoepidemiol Drug Saf 11:671–676PubMedCrossRef Gupta M, Shafiq N, Kumari S, Pandhi P (2002) Patterns and perceptions of complementary and alternative medicine (CAM) among leukaemia patients visiting haematology clinic of a north Indian tertiary care hospital. Pharmacoepidemiol Drug Saf 11:671–676PubMedCrossRef
21.
go back to reference Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK (2007) Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol 25:548–554PubMedCrossRef Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK (2007) Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol 25:548–554PubMedCrossRef
22.
go back to reference Kappauf H, Leykauf-Ammon D, Bruntsch U et al (2000) Use of and attitudes held towards unconventional medicine by patients in a department of internal medicine/oncology and haematology. Support Care Cancer 8:314–322PubMedCrossRef Kappauf H, Leykauf-Ammon D, Bruntsch U et al (2000) Use of and attitudes held towards unconventional medicine by patients in a department of internal medicine/oncology and haematology. Support Care Cancer 8:314–322PubMedCrossRef
23.
go back to reference Lerner IJ, Kennedy BJ (1992) The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin 42:181–191PubMedCrossRef Lerner IJ, Kennedy BJ (1992) The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin 42:181–191PubMedCrossRef
24.
go back to reference MacLennan AH, Myers SP, Taylor AW (2006) The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 184:27–31PubMed MacLennan AH, Myers SP, Taylor AW (2006) The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 184:27–31PubMed
25.
go back to reference MacLennan AH, Wilson DH, Taylor AW (2002) The escalating cost and prevalence of alternative medicine. Prev Med 35:166–173PubMedCrossRef MacLennan AH, Wilson DH, Taylor AW (2002) The escalating cost and prevalence of alternative medicine. Prev Med 35:166–173PubMedCrossRef
26.
go back to reference Moschen R, Kemmler G, Schweigkofler H et al (2001) Use of alternative/complementary therapy in breast cancer patients—a psychological perspective. Support Care Cancer 9:267–274PubMedCrossRef Moschen R, Kemmler G, Schweigkofler H et al (2001) Use of alternative/complementary therapy in breast cancer patients—a psychological perspective. Support Care Cancer 9:267–274PubMedCrossRef
27.
go back to reference Paltiel O, Avitzour M, Peretz T et al (2001) Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 19:2439–2448PubMed Paltiel O, Avitzour M, Peretz T et al (2001) Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 19:2439–2448PubMed
28.
go back to reference Pearl PL, Robbins EL, Bennett HD, Conry JA (2005) Use of complementary and alternative therapies in epilepsy: cause for concern. Arch Neurol 62:1472–1475PubMedCrossRef Pearl PL, Robbins EL, Bennett HD, Conry JA (2005) Use of complementary and alternative therapies in epilepsy: cause for concern. Arch Neurol 62:1472–1475PubMedCrossRef
29.
go back to reference Perez-Cruz I, Carcamo JM, Golde DW (2003) Vitamin C inhibits FAS-induced apoptosis in monocytes and U937 cells. Blood 102:336–343PubMedCrossRef Perez-Cruz I, Carcamo JM, Golde DW (2003) Vitamin C inhibits FAS-induced apoptosis in monocytes and U937 cells. Blood 102:336–343PubMedCrossRef
30.
go back to reference Perez-Cruz I, Carcamo JM, Golde DW (2007) Caspase-8 dependent trail-induced apoptosis in cancer cell lines is inhibited by vitamin C and catalase. Apoptosis 12:225–234PubMedCrossRef Perez-Cruz I, Carcamo JM, Golde DW (2007) Caspase-8 dependent trail-induced apoptosis in cancer cell lines is inhibited by vitamin C and catalase. Apoptosis 12:225–234PubMedCrossRef
31.
go back to reference Rai KR, Chiorazzi N (2003) Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 348:1797–1799PubMedCrossRef Rai KR, Chiorazzi N (2003) Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 348:1797–1799PubMedCrossRef
32.
go back to reference Richardson MA, Masse LC, Nanny K, Sanders C (2004) Discrepant views of oncologists and cancer patients on complementary/alternative medicine. Support Care Cancer 12:797–804PubMedCrossRef Richardson MA, Masse LC, Nanny K, Sanders C (2004) Discrepant views of oncologists and cancer patients on complementary/alternative medicine. Support Care Cancer 12:797–804PubMedCrossRef
33.
go back to reference Richardson MA, Sanders T, Palmer JL et al (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed Richardson MA, Sanders T, Palmer JL et al (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed
34.
go back to reference Risberg T, Kolstad A, Cassileth BR (2002) Use of alternative medicine among Norwegian cancer patients is associated with mental distress—a follow-up study. Acta Oncol 41:646–651PubMedCrossRef Risberg T, Kolstad A, Cassileth BR (2002) Use of alternative medicine among Norwegian cancer patients is associated with mental distress—a follow-up study. Acta Oncol 41:646–651PubMedCrossRef
35.
go back to reference Shanafelt TD, Lee YK, Call TG et al (2006) Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 30:707–712PubMedCrossRef Shanafelt TD, Lee YK, Call TG et al (2006) Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 30:707–712PubMedCrossRef
36.
go back to reference Sollner W, Maislinger S, DeVries A et al (2000) Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: a survey. Cancer 89:873–880PubMedCrossRef Sollner W, Maislinger S, DeVries A et al (2000) Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: a survey. Cancer 89:873–880PubMedCrossRef
37.
go back to reference Straus SE (2000) Complementary and alternative medicine: challenges and opportunities for American medicine. Acad Med 75:572–573PubMedCrossRef Straus SE (2000) Complementary and alternative medicine: challenges and opportunities for American medicine. Acad Med 75:572–573PubMedCrossRef
38.
go back to reference Styczynski J, Wysocki M (2006) Alternative medicine remedies might stimulate viability of leukemic cells. Pediatr Blood Cancer 46:94–98PubMedCrossRef Styczynski J, Wysocki M (2006) Alternative medicine remedies might stimulate viability of leukemic cells. Pediatr Blood Cancer 46:94–98PubMedCrossRef
39.
go back to reference Styczynski J, Wysocki M (2006) In vitro leukemic cell viability in the presence of alternative remedies might be related to in vivo drug resistance. Pediatr Blood Cancer 49(1):106CrossRef Styczynski J, Wysocki M (2006) In vitro leukemic cell viability in the presence of alternative remedies might be related to in vivo drug resistance. Pediatr Blood Cancer 49(1):106CrossRef
Metadata
Title
Complementary and alternative medicine in patients with chronic lymphocytic leukemia
Authors
Manfred Hensel
Martin Zoz
Anthony D. Ho
Publication date
01-01-2009
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 1/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0452-y

Other articles of this Issue 1/2009

Supportive Care in Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine